FDA approved prefilled syringe of Cortrophin Gel, noting strong uptake and concurrent discussion of Trump-era tariffs.

1 report, 1 independent Updated Sep 2

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA Donald Trump ANI Pharmaceuticals (United States)

Keep exploring

Part of

FDA approved medications targeting neurological conditions on September 5, 2025, while an aggressive tariff plan caused markets to tank. All 2 developments

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
- Trump ended the ceasefire agreement with Iran following recent attacks by Iranian forces.Mon 18:02
- The Trump administration utilized the Department of Health & Human Services for an AI tool.Mon 18:02
ANI Pharmaceuticals (United States)
company in Baudette, United States
- Trump's pledge to unleash oil and gas benefits stocks, involving Willis Towers Watson.Sun 05:14

Coverage

Newest first; wire copies grouped

Sep 2Insider MonkeyANI Pharmaceuticals, Inc. (ANIP) Hits Milestone with Cortrophin Gel Prefilled Syringe Launch We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. ANI Pharmaceutica